Ovarian stimulation and ovulation induction

Handbook of the Assisted Reproduction Laboratory

Volumn , Issue , 2000, Pages 139-178

  Maclin, Victoria M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4344634079     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (167)

1. Guzick, D.S., Carson, S.A., Coutifaris, C. et al., Efficacy of supraovulation and intrauterine insemination in the treatment of infertility, N. Engl. J. Med., 340, 177, 1999.
2. Guzick, D.S., Sullivan, M.W., Adamson, G.D. et al., Efficacy of treatment for unexplained infertility, Fertil. Steril., 70, 207, 1998.
3. Tummon, I.S., Asher, J.L., Martin, J.S.B., and Tulandi, T., Randomized control of trial of supraovulation and insemination and infertility associated with minimal or mild endometriosis, Fertil. Steril., 68, 8, 1997.
4. Fedele, L., Bianchi, S., Marchini, M., Villa, L., Brioschi, D., and Parazzini, F., Superovulation with human menopausal gonadotropins in the treatment of infertility associated with minimal or mild endometriosis: a controlled randomized study, Fertil. Steril., 58, 28-31, 1992.
5. Soto-Albors, C., Dailey, D.C., and Ying, Y.-K., Efficacy of human menopausal gonadotropins as therapy for abnormal cervical mucus, Fertil. Steril., 51, 58, 1989.
6. Glazener, C.M.A., Coulson, C., Lambert, P.A., Watt, E.M., Hinton, R.A., Kelly, N.G., and Hull, M.G.R., Clomiphene treatment for women with unexplained infertility: placebo controlled study of hormonal responses and conception rates, Gynecol. Endocrinol., 4, 75-83, 1990.
7. Wellner, S., DeCherney, A.H., and Polan, M.L., Human menopausal gonadotropins: a justifiable therapy in ovulatory women with longstanding idiopathic infertility, Am. J. Obstet. Gynecol., 58, 111-17, 1988.
8. Melis, G.B., Paoletti, A.M., Strigini, F., Fabrais, F.M., Canale, D., and Fioretti, P., Pharmacologic induction of multiple follicular development improves the success rate of artificial insemination with husband’s semen in couples with male related or unexplained infertility, Fertil. Steril., 47, 441-45, 1987.
9. Serafini, P., Stone, B., Kerin, J., Batzofin, J., Queen, P., and Marrs, R.P., An alternate approach to controlled ovarian hyperstimulation in “poor responders”: pretreatment with a gonadotropin releasing hormone analog, Fertil. Steril., 49, 90-95, 1988.
10. Tummon, I.S., Maclin, V.M., Radwanska, E., Binor, Z., and Dmowski, W.P., Occult ovulatory dysfunction in women with minimal endometriosis or unexplained infertility, Fertil. Steril., 50, 716-20, 1988.
11. Nulsen, J.C., Walsh, S., Dumez, S., and Metzger, D.A., A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination and the treatment of infertility, Obstet. Gynecol., 82, 780-6, 1993.
12. Jennings, J.C., Moreland, K., and Peterson, C.M., In vitro fertilisation: a review of drug therapy and clinical management, Drugs, 52, 331-43, 1996.
13. Fauser, B.C.J.M. and Van Heusden, A.M.V., Manipulation of human ovarian function: physiological concepts and clinical consequences, Endocrine Reviews, 18, 71-104, 1997.
14. Erickson, G.F., Physiologic basis of ovulation induction, Semin. Reprod. Endocrinol., 14, 287-97, 1996.
15. Gougeon, A., Dynamics of follicular growth in the human: a model from preliminary results, Hum. Reprod., 2, 81-87, 1986.
16. Hillier, S.G., Roles of follicle stimulating hormone and luteinizing hormone in controlled ovarian hyperstimulation, Hum. Reprod., 11 Suppl 3, 113-21, 1996.
17. Speroff, L., Glass, R.H., and Kase, N.G., Regulation of the menstrual cycle, in Clinical Gynecologic Endocrinology and Infertility, 5th ed., Williams and Wilkins, Baltimore, MD, c. 1994, 183-230.
18. McNatty, K.P., Hunter, W.M., McNeilly, A.S. et al., Change in the concentration of pituitary and steroid hormones in the follicular fluid of human Graafian follicles throughout the menstrual cycle, J. Endocrinol., 64, 555-71, 1975.
19. Brown, J.B., Pituitary control of ovarian function: concepts derived from gonadotropin therapy, Aust. NZ J. Obstet. Gynaecol., 18, 47-54, 1978.
20. Van Weissenbruch, M.M., Schoemaker, H.C., Drexhage, H.A., and Schoemaker, J., Pharmaco-dynamics of human menopausal gonadotropin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease, Hum. Reprod., 8, 813-21, 1993.
21. Van Der Meer, M., Hompes, P.G.A., Scheele, F., Schoute, E., Veersema, S., and Schoemaker, J., Follicle stimulating hormone (FSH) dynamics of low dose step-up ovulation induction with FSH in patients with polycystic ovary syndrome, Hum. Reprod., 9, 1612-17, 1994.
22. Fauser, B.C., Donderwinkel, P., and Schoot, D.C., The step-down principle in gonadotropin treatment and the role of GnRh analogues, Baillieres Clin. Obstet. Gynaecol., 7, 309-30, 1993.
23. Fathalla, M.F., Incessant ovulation-a factor in ovarian neoplasia?, Lancet, 2, 163, 1971.
24. Fishel, S. and Jackson, P., Follicular stimulation for high tech pregnancies: are we playing it safe?, Br. Med. J., 299, 309-11, 1989.
25. Whittemore, A.S., Harris, R., and Itnyre, J., The Collaborative Ovarian Cancer Group. Characteristics related to ovarian cancer risk: collaborative analysis of twelve US case-control studies. II. Invasive epithelial cancer in white women, Am. J. Epidemiol., 136, 1184-1203, 1992.
26. Harris, R., Whittemore, A.S., and Intyre, J., The Collaborative Ovarian Cancer Group. Characteristics related to ovarian cancer risk: collaborative analysis of twelve US case-control studies. III. Epithelial tumors of low malignant potential in white women, Am. J. Epidemiol., 136, 1204-11, 1992.
27. Rossing, M.A., Daling, J.R., Weiss, N.S., Moore, D.E., and Self, S.G., Ovarian tumors in a cohort of infertile women, N. Engl. J. Med., 331, 771-6, 1994.
28. Shushan, A. Paltiel, O., Iscovich, J., Elchalal, U., Peretz, T., and Schenker, J.G., Human menopausal gonadotropin and the risk of epithelial ovarian cancer, Fertil. Steril., 65, 13-18, 1996.
29. Bristow, R.E. and Karlan, B.Y., Ovulation induction, infertility, and ovarian cancer risk, Fertil. Steril., 66, 499-507, 1996.
30. Mosgaard, B.J., Lidegaard, O., Kruger-Kjaer, S., Schou, G., and Andersen, A.N., Infertility, fertility drugs, and invasive ovarian cancer: a case-control study, Fertil. Steril., 67, 1005-1012, 1997.
31. Potashnik, G., Lerner-Geva, L., Genkin, L., Chetrit, A., Lunenfeld, G., and Porath, A., Fertility drugs and the risk of breast and ovarian cancers: results of a long term followup study, Fertil. Steril., 71, 853-59, 1999.
32. Derman, S.G. and Adashi, E.Y., Adverse effects of fertility drugs, Drug Saf., 11, 408-21, 1994.
33. Bonhoff, A.J., Naether, O.G., and Johannisson, E., Effects of clomiphene citrate stimulation on endometrial structure in infertile women, Hum. Reprod., 11, 844-49, 1996.
34. Hock, D.L., Bohrer, M.K., Ananth, C.V., and Kemmann, G., Sonographic assessment of endometrial pattern and thickness inpatients treated with clomiphene citrate, human menopausal gonadotropins and intrauterine insemination, Fertil. Steril., 68, 242, 1997.
35. Physician’s Desk Reference. 53rd edition, Medical Economics Company, Inc., Montvale, NJ, c. 1999, 2995-97.
36. Bassil, S., Godin, P.A., Stallert, S., Nisolle, M., De Cooman, S., Donnez, J., and Gordts, S., Ovarian hyperstimulation syndrome: a review, Assisted Reprod. Rev., 5, 90-96, 1995.
37. Navot, D., Margolioth, E.J., Laufer, N., Birkenfeld, A., Relon, A., Rosler, A., and Schenker, J.G., Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome, Fertil. Steril., 48, 57-61, 1987.
38. Ong, A.C.M., Eisen, V., Rennie, D.P., Homburg, R., Lachelin, G.C.L., Jacobs, H.S., and Slater, J.D.H., The pathogenesis of the ovarian hyperstimulation syndrome (OHS): A possible role for ovarian renin, Clin. Endocrinol., 34, 43-49, 1991.
39. Schenker, J.G. and Polishuk, W.Z., An experimental model of ovarian hyperstimulation syndrome, in Proc. Int. Congress Animal Reprod., Vol 4, Tischner, M. and Pilc, J., Eds., Drukarnia Naukowa, Krakow, 1976, 635.
40. Knox, G.E., Dowd, A., Spiesel, S., and Hong, R., Antihistamine blockade of the ovarian hyperstimulation syndrome. II. Possible role of antigen-antibody complexes in the pathogenesis of the syndrome, Fertil. Steril., 26, 418-21, 1975.
41. Balasch, J., Arroyo, V., Carmona, F., Llach, J., Jimenez, W., Pare, J.C., and Vanrell, J.A., Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation, Fertil. Steril., 56, 1077-83, 1991.
42. Erlik, Y., Naot, Y., Friedman, M., Ben-David, E., and Paldi, E., Histamine levels in ovarian hyperstimulation syndrome, Obstet. Gynecol., 53, 580-82, 1979.
43. Haning, R.V., Strawn, E.Y., and Nolten, W.E., Pathophysiology of the ovarian hyperstimulation syndrome, Obstet. Gynecol., 66, 220-24, 1985.
44. Doldi, N., Bassan, M., Messa, A., and Ferrari, A., Expression of vascular endothelial growth factor in human luteinizing granulosa cells and its correlation with the response to controlled ovarian hyperstimulation, Gynecol. Endocrinol., 11, 263-7, 1997.
45. McClure, N., Healy, D.L., Rogers, P.A.W., Sullivan, J., Beaton, L., Haning, R.V. et al., Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome, Lancet, 344, 235-6, 1994.
46. Neulen, J., Yan, Z., Raczek, S., Weindel, K., Keck, C., Weich, H.A. et al., Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome, J. Clin. Endocrinol. Metab., 80, 1967-71, 1995.
47. Christenson, L.K. and Stouffer, R.L., Follicle stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells and from pre-and periovulatory follicles, J. Clin. Endocrinol. Metab., 82, 2135-40, 1997.
48. Tanbo, T., Dale, P.O., Kjekshus, E., Haug, E., and Abyholm, T., Stimulation with human menopausal gonadotropin versus follicle stimulating hormone after pituitary suppression in polycystic ovarian syndrome, Fertil. Steril., 53, 798-803, 1990.
49. Larsen, T., Larsen, J.F., Schioler, V., Bostofte, E., and Felding, C., Comparison of urinary follicle stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome, Fertil. Steril., 53, 426-31, 1990.
50. Physician’s Desk Reference. 53rd edition, Medical Economics Company, Inc., Montvale, NJ, c. 1999, 2988-89.
51. Howles, C.M., Genetic engineering of human FSH (Gonal-F), Hum. Reprod. Update, 2, 172-91, 1996.
52. Loumaye, E., Campbell, R., and Salat-Baroux, J., Human follicle stimulating hormone produced by recombinant DNA technology: a review for clinicians, Hum. Reprod. Update, 1, 188-99, 1995.
53. Bergh, C., Howles, C.M., Borg, K., Hamberger, L., Josefsson, B., Nilsson, L., and Wikland, M., Recombinant human follicle stimulating hormone (r-hFSH; Gonal F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques, Hum. Reprod., 12, 2133-2139, 1997.
54. Physician’s Desk Reference. 53rd edition, Medical Economics Company, Inc., Montvale, NJ, c. 1999, 2997-98.
55. Hugues, J.N. and Durnerin, C., Revisiting gonadotropin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotropins, Hum. Reprod. Update, 4, 83-101, 1998.
56. Racowsky, C., Prather, A.L., Johnson, M.K., Olvera, S.P., and Gelety, T.J., Prematurely condensed chromosomes and meiotic abnormalities in unfertilized human oocytes after ovarian stimulation with and without gonadotropin-releasing hormone agonist, Fertil. Steril., 67, 932-8, 1997.
57. Plachot, M., Veiga, A., Montagut, J., de Grouchy, J., Calderon, G., Lepretre, S. et al., Are clinical and biological IVF parameters correlated with chromosomal disorders in early life?, Hum. Reprod., 3, 627-35, 1988.
58. Physician’s Desk Reference. 53rd edition, Medical Economics Company, Inc., Montvale, NJ, c. 1999, 3136-37.
59. Scott, R.T. and Hofmann, G.E., Prognostic assessment of ovarian reserve, Fertil. Steril., 63, 1-11, 1995.
60. Scott, R.T., Toner, J.P., Muasher, S.J., Oehninger, S., Robinson, S., and Rosenwaks, Z., Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome, Fertil. Steril., 651-654, 1989.
61. Ramey, J.W., Seltman, H.J., and Toner, J.P., Superior analytic characteristics of an immunometric assay for gonadotropins also provides useful clinical prediction of in vitro fertilization outcomes, Fertil. Steril., 65, 661-3, 1996.
62. Seifer, D.B., Lambert-Messerlian, G., Hogan, J.W., Gardiner, A.C., Blazer, A.S., and Berk, C.A., Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome, Fertil. Steril., 67, 110-4, 1997.
63. Hofmann, G.E., Danforth, D.R., and Seifer, D.B., Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening, Fertil. Steril., 69, 474-7, 1998.
64. Scott, R.T., Hofmann, G.E., Oehninger, S., and Muasher, S.J., Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization, Fertil. Steril., 54, 297-302, 1990.
65. Smotrich, D.B., Widra, E.A., Gindoff, P.R., Levy, M.J., Hall, J.L., and Stillman, R.J., Prognostic value of day 3 estradiol on in vitro fertilization outcome, Fertil. Steril., 64, 1136-40, 1995.
66. Buyalos, R.P., Daneshmand, S., and Brzechffa, P.R., Basal estradiol and folliclestimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy, Fertil. Steril., 68, 272-7, 1997.
67. Evers, J.L.H., Slaats, P., Land, J.A., Dumoulin, J.C.M., and Dunselman, A.J., Elevated levels of basal estradiol-17 B predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization, Fertil. Steril., 69, 1010-4, 1998.
68. Mukherjee, T., Copperman, A.B., Lapinski, R., Sandler, B., Bustillo, M., and Grunfeld, L., An elevated day 3 follicle-stimulating hormone:luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation, Fertil. Steril., 65, 588-93, 1996.
69. Padilla, S.L., Bayati, J., and Garcia, J.E., Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization, Fertil. Steril., 53, 288-294, 1990.
70. Winslow, K.L., Toner, J.P., Brzyski, R.G., Oehninger, S.C., Acosta, A.A., and Muasher, S.J., The gonadotropin-releasing hormone agonist stimulation test-a sensitive predictor of performance in the flare-up in vitro fertilization cycle, Fertil. Steril., 56, 711-17, 1991.
71. Ranieri, D.M., Quinn, F., Maklouf, A., Khadum, I., Ghutmi, W., McGarrigle, H., Davies, M., and Serhal, P., Simultaneous evaluation of basal follicle-stimulating and 17 B-estradiol response to gonadotropin-releasing hormone analogue stimulation: an improved predictor of ovarian reserve, Fertil. Steril., 70, 227-33, 1998.
72. Chang, M.Y., Chiang, C.H., Hsieh, T.T., Soong, Y.K., and Hsu, K.H., Use of the antral follicle count to predict the outcome of assisted reproductive technologies, Fertil. Steril., 69, 505-10, 1998.
73. Tomas, C., Nuojua-Huttunen, S., and Martikainen, H., Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotropins in in vitro fertilization, Hum. Reprod., 12, 220-3, 1997.
74. Chang, M.Y., Chiang, C.H., Chiu, T.H., Hsieh, T.T., and Soong, Y.K., The antral follicle count predicts the outcome of pregnancy in a controlled ovarian hyperstimulation/intrauterine insemination program, J. Assist. Reprod. Genet., 15, 12-17, 1998.
75. Tanbo, T., Dale, P.O., Lunde, O., Norman, N., and Abyholm, T., Prediction of response to controlled ovarian hyperstimulation: a comparison of basal and clomiphene citrate-stimulated follicle-stimulating hormone levels, Fertil. Steril., 57, 819-24, 1992.
76. Navot, D., Rosenwaks, Z., and Margolioth, E.J., Prognostic assessment of female fecundity, Lancet, 2, 645-47, 1987.
77. Loumaye, E., Billion, J.M., Mine, J.M., Psalti, I., Pensis, M., and Thomas, K., Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test, Fertil. Steril., 53, 295-301, 1990.
78. Scott, R.T., Leonardi, M.R., Hofmann, G.E., Illions, E.H., Neal, G.S., and Navot, D., A prospective evaluation of clomiphene citrate challenge test screening of the general infertility population, Obstet. Gynecol., 82, 539-44, 1993.
79. Hofmann, G.E., Sosnowski, J., Scott, R.T., and Thie, J., Efficacy of selection criteria for ovarian reserve screening using the clomiphene citrate challenge test in a tertiary fertility center population, Fertil. Steril., 66, 49-53, 1996.
80. Scott, R.T., Opsahl, M.S., Leonardi, M.R., Neall, G.S., Illions, E.H., and Navot, D., Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age, Hum. Reprod., 10, 1706-10, 1995.
81. Lim, A.S.T. and Tsakok, M.F.H., Age-related decline in fertility: a link to degenerative oocytes?, Fertil. Steril., 68, 265-71, 1997.
82. Munne, S., Lee, A., Rosenwaks, Z., Grifo, J., and Cohen, J., Diagnosis of major chromosome aneuploidies in human preimplantation embryos, Hum. Reprod., 8, 2185-91, 1993.
83. Benadiva, C.A., Kligman, I., Munne, S., Aneuploidy 16 in human embryos increases significantly with maternal age, Fertil. Steril., 66, 248-55, 1996.
84. Battaglia, D.E., Goodwin, P., Klein, N.A., and Soules, M.R., Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women, Hum. Reprod., 11, 2217-22, 1996.
85. Hanoch, J., Lavy, Y., Holzer, H., Hurwitz, A., Simon, A., Revel, A., and Laufer, N., Young low responders protected from untoward effects of reduced ovarian response, Fertil. Steril., 69, 1001-04, 1998.
86. Kettel, L.M. and Hummel, W.P., Ovulation induction in the estrogenized anovulatory patient, Semin. Reprod. Endocrinol., 14, 309-15, 1996.
87. Ergur, A.R., Yergok, Y.Z., Ertekin, A., Kucuk, T., Mungen, E., and Tutuncu, L., Clomiphene citrate-resistant polycystic ovary syndrome: preventing multifollicular development, J. Reprod. Med., 43, 185-90, 1998.
88. Van Voorhis, B.J., Sparks, A.E.T., Allen, B.D., Stovall, D.W., Syrop, C.H., and Chapler, F.K., Cost-effectiveness of infertility treatments: a cohort study, Fertil. Steril., 67, 830-6, 1997.
89. Tummon, I.S., Maclin, V.M., Radwanska, E., Binor, Z., and Dmowski, W.P., Occult ovulatory dysfunction in women with minimal endometriosis or unexplained infertility, Fertil. Steril., 50, 716-20, 1988.
90. Bohrer, M.K., Hock, D.L., Rhoads, G.G., and Kemmann, E., Sonographic assessment of endometrial pattern and thickness in patients treated with human menopausal gonadotropins, Fertil. Steril., 66, 244-47, 1996.
91. Ransom, M.X., Doughman, N.C., and Garcia, A.J., Menotropins alone are superior to a clomiphene citrate and menotropin combination for superovulation induction among clomiphene citrate failures, Fertil. Steril., 65, 1169-74, 1996.
92. Gentry, W.L., Thomas, S., and Critser, E.S., Use of endometrial measurement as an exclusion criterion for in vitro fertilization using clomiphene citrate, J. Reprod. Med., 41, 545-47, 1996.
93. Tohma, H., Hasegawa, I., Sekizuka, N., and Tanaka, K., Uterine blood flow. Assessment in an intrauterine insemination program for unexplained infertility, J. Reprod. Med., 42, 463-66, 1997.
94. Lu, P.Y., Chen, A.L.J., Atkinson, E.J., Lee, S.H., Erickson, L.D., and Ory, S.J., Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility, Fertil. Steril., 65, 583-87, 1996.
95. Balasch, J., Fabregues, F., Creus, M., Moreno, V., Puerto, B., Penarrubia, J., Carmona, F., and Vanrell, J.A., Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin for ovarian stimulation after pituitary suppression in in vitro fertilization, Hum. Reprod., 11, 2400-04, 1996.
96. Balasch, J., Fabregues, F., Penarrubia, J., Creus, M., Vidal, R., Casamitjana, R., Manau, D., and Vanrell, J.A., Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO group II anovulatory infertile patients, J. Assist. Reprod. Genet., 15, 552-59, 1998.
97. Bennink, H.J.T.C., Fauser, B.C.J.M., and Out, H.J., Recombinant folliclestimulation hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial, Fertil. Steril., 69, 19-25, 1998.
98. Homburg, R., Levy, T., Berkovitz, D., Farchi, J., Feldberg, D., Ashkenazi, J. et al., Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome, Fertil. Steril., 59, 527-31, 1993.
99. Sagle, M., Bishop, K., Ridley, N., Alexander, F.M., Michel, M., Bonney, R.C. et al., Recurrent early miscarriage and polycystic ovaries, Br. Med. J., 297, 1027-8, 1988.
100. Homburg, R., Armar, N.A., Eshel, A., Adams, J., and Jacobs, H.S., Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome, Br. Med. J., 297, 1024-6, 1988.
101. Romeu, A., Monzo, A., Peiro, T., Diez, E., Peinado, J.A., and Quintero, L.A., Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles, J. Assist. Reprod. Genet., 14, 518-24, 1997.
102. Lewit, N., Kol, S., Manor, D., and Itskovitz-Eldor, J., Comparison of gonadotropinreleasing hormone analogues and human chorionic gonadotropin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study, Hum. Reprod., 11, 1399-1402, 1996.
103. Di Donato, P., Nola, V.F., Pittman, T.V., Marr, V., Stubbs, C., and Meldrum, D.R., Leuprolide acetate for inducing ovulation in women undergoing ovarian stimulation, J. Reprod. Med., 40, 715-16, 1995.
104. Scott, R.T., Evaluation and treatment of low responders, Semin. Reprod. Endocrinol., 14, 317-37, 1996.
105. Hofmann, G.E., Toner, J.P., Muasher, S.J., and Jones, G.S., High-dose follicle stimulating hormone (FSH) ovarian stimulation in low responder patients for in vitro fertilization, J. In Vitro Fert. Embryo Transfer, 6, 285-89, 1993.
106. Sungurtekin, U. and Jansen, R.P.S., Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate, Fertil. Steril., 63, 663-5, 1995.
107. Surrey, E.S., Bower, J., Hill, D.M., Ramsey, J., and Surrey, M.W., Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization, Fertil. Steril., 69, 419-24, 1998.
108. Greenblatt, E.M., Meriano, J.S., and Casper, R.F., Type of stimulation protocol affects oocyte maturity, fertilization rate, and cleavage rate after intracytoplasmic sperm injection, Fertil. Steril., 64, 557-63, 1995.
109. Scott, R.T. and Navot, D., Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization, Fertil. Steril., 61, 880-5, 1994.
110. Schoolcraft, W., Schlenker, T., Gee, M., Stevens, J., and Wagley, L., Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol, Fertil. Steril., 67, 93-7, 1997.
111. Suikara, A.M., Maclachlan, V., Koistinen, R., Seppala, M., and Healy, D.L., Doubleblind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology, Fertil. Steril., 65, 800-5, 1996.
112. Smitz, J., Devroey, P., Braekmans, P., Camus, M., Khan, I., Staessen, C. et al., Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and hMG, Hum. Reprod., 2, 309-14, 1987.
113. Ron-El, R., Herman, A., Golan, A. et al., The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist, Fertil. Steril., 54, 233-37, 1990.
114. Urbancsek J. and Witthaus, E., Midluteaal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization, Fertil. Steril., 65, 966-71, 1996.
115. Knodaveeti-Gordon, U., Harrison, R.F., Barry-Kinsella, C., Gordon, A.C., Drudy, L., and Cottell, E., A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program, Fertil. Steril., 66, 582-6, 1996.
116. Devreker, F., Govaerts, I., Bertrand, E., Van den Bergh, M., Gervey, C., and Englert, Y., The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate, Fertil. Steril., 65, 122-6, 1996.
117. Fabregues, F., Balasch, J., Creus, M., Civico, S., Carmona, F., Puerto, B., and Vanrell, J.A., Long term down-regulation does not improve pregnancy rates in an in vitro fertilization program, Fertil. Steril., 70, 46-51, 1998.
118. Simon, C., Velasco, J.J.G., Valbuena, D., Peinado, J.A., Moreno, C., Remohi, J., and Pellicer, A., Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen, Fertil. Steril., 70, 234-9, 1998.
119. Tortoriello, D.V., McGovern, P.G., Colon, J.M., Skurnick, J.H., Lipetz, K., and Santoro, N., “Coasting” does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients, Fertil. Steril., 69, 454-60, 1998.
120. Tiitinen, A., Husa, L.M., Tulppala, M., Simberg, N., and Seppala, M., The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome, Br. J. Obstet. Gynaecol., 102, 326-9, 1995.
121. Dahl Lyons, C.A., Wheeler, C.A., Frishman, G.N., Hackett, R.J., Seifer, D.B., and Haning, R.V., Early and late presentation of ovarian hyperstimulation syndrome: two distinct entities with different risk factors, Hum. Reprod., 9, 792-9, 1994.
122. Paulson, R.J., Sauer, M.V., and Lobo, R.A., Embryo implantation after human in vitro fertilization: importance of endometrial receptivity, Fertil. Steril., 53, 870-4, 1990.
123. Kowalik, A., Barmat, L., Damario, M., Liu, H.-C., Davis, O., and Rosenwaks, Z., Ovarian estradiol production in vivo: inhibitory effect of leuprolide acetate, J. Reprod. Med., 43, 413-17, 1998.
124. Corson, S.L., Batzer, F.R., Gocial, B., Eisenberg, E., Hupert, L.C., and Nelson, J.R., Leuprolide acetate-prepared in vitro fertilization-gamete intrafallopian transfer cycles: efficacy versus controls and cost analysis, Fertil. Steril., 57, 601-5, 1992.
125. Pantos, K., Meimeth-Damianaki, T., Vaxevanoglou, T., and Kapetanakis, E., Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program, Fertil. Steril., 61, 709-13, 1994.
126. Fujii, S., Sagara, M., Kudo, H., Kagiya, A., Sato, S., and Saito, Y., A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization, Fertil. Steril., 67, 1166-6, 1997.
127. Faber, B.M., Mayer, J., Cox, B., Jones, D., Toner, J.P., Oehninger, S., and Muasher, S.J., Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders, Fertil. Steril., 69, 826-30, 1998.
128. Benadiva, C.A., Davis, O., Kligman, I., Liu, H.C., and Rosenwaks, Z., Clomiphene citrate and HMG: an alternative stimulation protocol for selected failed in vitro fertilization patients, J. Assist. Reprod. Genet., 12, 8-12, 1995.
129. Noyes, R.W., The underdeveloped secretory endometrium, Am. J. Obstet. Gynecol., 77, 929-44, 1959.
130. Zorn, J.R., Cedard, L., Nessmann, C., and Savale, M., Delayed endometrial maturation in women with normal progesterone levels: the dysharmonic luteal phase syndrome, Gynecol. Obstet. Invest., 17, 157-62, 1984.
131. Batista, M.C., Cartledge, T.P., Merino, M.J., Axiotis, C., Platia, M.P., Merriam, G.R. et al., Midluteal phase endometrial biopsy does not accurately predict luteal function, Fertil. Steril., 59, 294-300, 1993.
132. Gidley-Baird, A.A., O’Neill, C., Sinosich, M.J., Proter, R.N., Pike, I.L., and Saunders, D.M., Failure of implantation in human in vitro fertilization and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice, Fertil. Steril., 45, 69-74, 1986.
133. Maclin, V.M., Radwanska, E., Binor, Z., and Dmowski, W.P., Progesterone:estradiol ratios at implantation in ongoing pregnancies, abortions and nonconception cycles resulting from ovulation induction, Fertil. Steril., 54, 238-44, 1990.
134. Abd-el-Maeboud, K.H., Eissa, S., and Kamel, A.S., Altered endometrial progesterone/oestrogen receptor ratio in luteal phase defect, Dis. Markers, 13, 107-16, 1997.
135. Hirama, Y. and Ochiai, K., Estrogen and progesterone receptors of the out-of-phase endometrium in female infertile patients, Fertil. Steril., 63, 984-8, 1995.
136. DiZerega, G.S. and Hodgen, G.D., Follicular phase treatment of luteal phase dysfunction, Fertil. Steril., 35, 428, 1981.
137. Huang, K., Muechler, E.K., and Bonfiglio, T.A., Follicular phase treatment of luteal phase defect with follicle-stimulating hormone in infertile women, Obstet. Gynecol., 64, 32, 1984.
138. Minassian, S.S., Wu, C.H., Groll, M., Gocial, B., and Goldfarb, A.F., Urinary follicle stimulating hormone treatment of luteal phase defect, J. Reprod. Med., 33, 11, 1988.
139. Muechler, E.K., Huang, K.-E., and Zongrone, J., Superovulation of habitual aborters with subtle luteal phase deficiency, Int. J. Fertil., 32, 359, 1987.
140. Shapiro, A.G., New treatment for the inadequate luteal phase, Obstet. Gynecol., 40, 826, 1972.
141. Olson, J.L., Rebar, R.W., Schreiber, J.F., and Vaitukaitis, J.L., Shortened luteal phase after ovulation induction with human menopausal gonadotropin and human chorionic gonadotropin, Fertil. Steril., 39, 284, 1983.
142. Laatikkainen, T., Kurunmaki, H., and Koshimies, A., A short luteal phase in cycles stimulated with clomiphene and human menopausal gonadotropin for in vitro fertilization, J. In Vitro Fert. Embryo Transfer, 5, 14, 1988.
143. Howles, C.M., Macnamee, M.C., and Edwards, R.G., Follicular development and early luteal function of conception and nonconception cycles after human in vitro fertilization: endocrine correlates, Hum. Reprod., 2, 17, 1987.
144. Berquist, C., Nillius, S.J., and Wide, L., Human gonadotropin therapy. II. Serum estradiol and progesterone patterns during nonconceptual cycles, Fertil. Steril., 39, 766, 1983.
145. Goldstein, D., Zuckerman, H., Harpaz, S., Barkai, J., Gera, A., Gordon, S., Shalev, E., and Schwartz, M., Correlation between estradiol and progesterone in cycles with luteal phase deficiency, Fertil. Steril., 37, 348, 1982.
146. Garcia, J., Jones, C., Agosta, A., and Wright, G., Corpus luteum function after follicle aspiration for oocyte retrieval, Fertil. Steril., 46, 903, 1981.
147. Smitz, J., Devroey, P., Camus, M., Deshacht, J., Khan, I., Staessen, C. et al., The luteal phase and early pregnancy after combined GnRH agonist/HMG treatment for superovulation in IVF or GIFT, Hum. Reprod., 3, 585, 1988.
148. Kubic, C.J., Luteal phase dysfunction following ovulation induction, Semin. Reprod. Endocrinol., 4, 293, 1986.
149. Van Steirteghem, A.C., Smitz, J., Camus, M., Van Waesberghe, L., Deschacht, J. et al., The luteal phase after in vitro fertilization and related procedures, Hum. Reprod., 3, 161, 1988.
150. Macnamee, M.C., Edwards, R.G., and Howles, C.M., The influence of stimulation regimens and luteal phase support on the outcome of IVF, Hum. Reprod., 3, 43, 1988.
151. Dehou, M.F., Lejeune, B., Arijs, C., and Leroy, F., Endometrial morphology in stimulated in vitro fertilization cycles and after steroid replacement therapy in cases of primary ovarian failure, Fertil. Steril., 48, 995, 1987.
152. Smith, E.M., Anthony, F.W., Gadd, S.C., and Masson, G.M., Trial of support treatment with human chorionic gonadotropin in the luteal phase after treatment with buserelin and human menopausal gonadotropin in women taking part in an in vitro fertilisation programme, Br. Med. J., 298, 1483, 1989.
153. Belaisch-Allart, J., DeMouzon, J., Lapouterie, C., and Mayer, M., The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme, Hum. Reprod., 5, 163, 1990.
154. Claman, P., Domingo, M., and Leader, A., Luteal phase support in in vitro fertilization using gonadotropin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotropin versus intramuscular progesterone, Hum. Reprod., 7, 487-9, 1992.
155. Araujo, E., Bernardini, J., Frederick, J.L., Asch, R.H., and Balmaceda, J.P., Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction, J. Assist. Reprod. Genet., 11, 74-78, 1994.
156. Artini, P.G., Volpe, A., Angioni, S., Galassi, M.C., Battaglia, C., and Genazzani, A.R., A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program, J. Endocrinol. Invest., 18, 51-6, 1995.
157. Buvat, J., Marcoiln, G., Herbaut, J.C., Dehaene, J.L., Verbeck, P., and Fourlinnie, J.C., A randomized trial human chorionic gonadotropin support following in vitro fertilization and embryo transfer, Fertil. Steril., 49, 458, 1988.
158. Navot, D., Bergh, P.A., and Laufer, N., Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment, Fertil. Steril., 58, 249-61, 1992.
159. Mochtar, M.H., Hogerzeil, H.V., and Mol, B.W., Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial, Hum. Reprod., 11, 1602-1605, 1996.
160. Kinel, F.A. and Ciaccio, L.A., Suppression of immune response by progesterone, Endocrinol. Exp., 14, 27, 1980.
161. Akande, A.V., Mathur, R.S., Keay, S.D., and Jenkins, J.M., The choice of luteal support following pituitary down regulation, controlled ovarian hyperstimulation and in vitro fertilisation, Br. J. Obstet. Gynecol., 103, 963-66, 1996.
162. Smitz, J., Devroey, P., Faguer, B., Bourgain, C., Camus, M., and Van Steirteghem, A.C., A prospective randomized comparison of intramuscular or intravaginal natural progesterone as luteal phase and early pregnancy supplement, Hum. Reprod., 7, 168-75, 1992.
163. Csapo, A.I., Pulkkinen, M.O., Ruttner, B., Sauvage, J.P., and Wiest, W.G., The significance of human corpus luteum in pregnancy maintenance, Am. J. Obstet. Gynecol., 112, 1061, 1972.
164. Lelaidler, C., de Ziegler, D., Freitas, S., Oliveness, F., Hazout, A., and Frydman, R., Endometrium preparation with exogenous estradiol and progesterone for the transfer of cryopreserved blastocysts, Fertil. Steril., 63, 919-21, 1995.
165. Miles, R.A., Paulson, R.J., Lobo, R.A., Press, M.F., Dahmoush, L., and Sauer, M.V., Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study, Fertil. Steril., 5, 276-81, 1990.
166. de Ziegler, D., Hormonal control of endometrial receptivity, Hum. Reprod., 10, 4-7, 1995.
167. Perino, M., Brigandi, A., Abate, F.G., Costabile, L., Balzano, E., and Abate, A., Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study, Clin. Exp. Obstet. Gynecol., 24, 228-31, 1997.